within Pharmacolibrary.Drugs.D_Dermatologicals.D11A_OtherDermatologicalPreparations.D11AH07_Tralokinumab;

model Tralokinumab
  extends Pharmacolibrary.Drugs.ATC.D.D11AH07;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>D11AH07</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tralokinumab is a human monoclonal antibody that specifically binds to and inhibits interleukin-13 (IL-13). It is used primarily for the treatment of moderate-to-severe atopic dermatitis in adults and has received approval in several regions including the US and EU.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with moderate to severe atopic dermatitis after subcutaneous administration; population includes both males and females, no specific comorbidity, typical adult weight.</p><h4>References</h4><ol><li><p>Jain, M, et al., &amp; van der Merwe, R (2017). Tralokinumab pharmacokinetics and tolerability when administered by different subcutaneous injection methods and rates . <i>International journal of clinical pharmacology and therapeutics</i> 55(7) 606–620. DOI:<a href=&quot;https://doi.org/10.5414/CP203023&quot;>10.5414/CP203023</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28590244/&quot;>https://pubmed.ncbi.nlm.nih.gov/28590244</a></p></li><li><p>Baverel, P, et al., &amp; Gevorkyan, H (2018). A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers. <i>Drug metabolism and pharmacokinetics</i> 33(3) 150–158. DOI:<a href=&quot;https://doi.org/10.1016/j.dmpk.2017.12.001&quot;>10.1016/j.dmpk.2017.12.001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29622380/&quot;>https://pubmed.ncbi.nlm.nih.gov/29622380</a></p></li><li><p>Soehoel, A, et al., &amp; Timmermann, S (2022). Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis. <i>Clinical pharmacology in drug development</i> 11(8) 910–921. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1113&quot;>10.1002/cpdd.1113</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35671038/&quot;>https://pubmed.ncbi.nlm.nih.gov/35671038</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Tralokinumab;
